<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id><journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id><journal-title-group><journal-title>BMC Research Notes</journal-title></journal-title-group><issn pub-type="epub">1756-0500</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6771106</article-id><article-id pub-id-type="publisher-id">4671</article-id><article-id pub-id-type="doi">10.1186/s13104-019-4671-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group></article-categories><title-group><article-title>Expression of microRNA in human retinal pigment epithelial cells following infection with <italic>Zaire ebolavirus</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oliver</surname><given-names>Genevieve F.</given-names></name><address><email>genevieve.oliver@flinders.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Orang</surname><given-names>Ayla V.</given-names></name><address><email>ayla.orang@flinders.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Appukuttan</surname><given-names>Binoy</given-names></name><address><email>binoy.appukuttan@flinders.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marri</surname><given-names>Shashikanth</given-names></name><address><email>shashikanth.marri@flinders.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Michael</surname><given-names>Michael Z.</given-names></name><address><email>michael.michael@flinders.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marsh</surname><given-names>Glenn A.</given-names></name><address><email>Glenn.Marsh@csiro.au</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4756-5493</contrib-id><name><surname>Smith</surname><given-names>Justine R.</given-names></name><address><email>justine.smith@flinders.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0367 2697</institution-id><institution-id institution-id-type="GRID">grid.1014.4</institution-id><institution>Flinders University College of Medicine and Public Health, </institution></institution-wrap>Flinders Medical Centre Room 4E-431, Flinders Drive, Bedford Park, SA 5042 Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.1016.6</institution-id><institution>Health and Biosecurity, Commonwealth Scientific and Industrial Research Organisation, </institution></institution-wrap>5 Portarlington Rd, Newcomb, VIC 3219 Australia </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>12</volume><elocation-id>639</elocation-id><history><date date-type="received"><day>5</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">Survivors of Ebola virus disease (EVD) are at risk of developing blinding intraocular inflammation&#x02014;or uveitis&#x02014;which is associated with retinal pigment epithelial (RPE) scarring and persistence of live <italic>Zaire ebolavirus</italic> (EBOV) within the eye. As part of a large research project aimed at defining the human RPE cell response to being infected with EBOV, this work focused on the microRNAs (miRNAs) associated with the infection.</p></sec><sec><title>Results</title><p id="Par2">Using RNA-sequencing, we detected 13 highly induced and 2 highly repressed human miRNAs in human ARPE-19 RPE cells infected with EBOV, including hsa-miR-1307-5p, hsa-miR-29b-3p and hsa-miR-33a-5p (up-regulated), and hsa-miR-3074-3p and hsa-miR-27b-5p (down-regulated). EBOV-miR-1-5p was also found in infected RPE cells. Through computational identification of putative miRNA targets, we predicted a broad range of regulatory activities, including effects on innate and adaptive immune responses, cellular metabolism, cell cycle progression, apoptosis and autophagy. The most highly-connected molecule in the miR-target network was leucine-rich repeat kinase 2, which is involved in neuroinflammation and lysosomal processing. Our findings should stimulate new studies on the impact of miRNA changes in EBOV-infected RPE cells to further understanding of intraocular viral persistence and the pathogenesis of uveitis in EVD survivors.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ebola</kwd><kwd>Filovirus</kwd><kwd>microRNA</kwd><kwd>Retina</kwd><kwd>Retinal pigment epithelium</kwd><kwd>Uveitis</kwd><kwd><italic>Zaire ebolavirus</italic></kwd></kwd-group><funding-group><award-group><funding-source><institution>Australian Research Council</institution></funding-source><award-id>FT130101648</award-id><principal-award-recipient><name><surname>Smith</surname><given-names>Justine R.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National Health &#x00026; Medical Research Council Australia</institution></funding-source><award-id>PGS1150282</award-id><principal-award-recipient><name><surname>Oliver</surname><given-names>Genevieve F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Flinders University Faculty of Medicine, Nursing and Health Sciences</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Avant Doctor-in-Training Scholarship</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par19">Survivors of Ebola virus disease (EVD) suffer long-term sequelae. Intraocular inflammation&#x02014;termed uveitis&#x02014;develops in 18&#x02013;34% of survivors [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], and 40% of affected persons become blind [<xref ref-type="bibr" rid="CR3">3</xref>]. Live <italic>Zaire ebolavirus</italic> (EBOV) has been isolated from intraocular fluid after resolution of the viremia [<xref ref-type="bibr" rid="CR4">4</xref>], and retinal scars that indicate involvement of the retinal pigment epithelium are associated with uveitis [<xref ref-type="bibr" rid="CR3">3</xref>]. <italic>Zaire ebolavirus</italic> may persist at immune-privileged sites, such as the eye, since local immune responses are attenuated to avoid tissue damage. We previously demonstrated that human retinal pigment epithelial (RPE) cells mount a type I interferon (IFN) anti-viral response and maintain immunomodulatory activity when infected with EBOV, and this cell population may be a reservoir for EBOV in the eye [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par20">MicroRNAs (miRNAs) are short (18&#x02013;22&#x000a0;nt) fragments of single-stranded RNA that bind the 3&#x02032; untranslated region of mRNA, and directly suppress or indirectly activate gene expression. Because only a small (7&#x02013;8&#x000a0;nt) &#x0201c;seed region&#x0201d; requires complementarity to permit binding, a single miRNA may have hundreds of mRNA targets, and thus play a complex regulatory role in cellular activity that varies by cell type and disease state [<xref ref-type="bibr" rid="CR6">6</xref>]. We used small RNA sequencing (RNA-Seq) to identify miRNA expression in EBOV-infected human RPE cells, and conducted in silico analyses to identify biological targets of, and molecular interactions with, these miRNAs.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Methods</title><p id="Par21">Total RNA was sourced from our previous study [<xref ref-type="bibr" rid="CR5">5</xref>], in which the human RPE cell line (ARPE-19) [<xref ref-type="bibr" rid="CR7">7</xref>] was infected in triplicate with EBOV (multiplicity of infection, 5) or mock-infected for 24&#x000a0;h. From 1&#x000a0;&#x003bc;g of RNA extract, small RNA was selectively enriched through sequential adapter ligation to 3&#x02032; and 5&#x02032; ends of RNA fragments using the TruSeq Small RNA Library Preparation Kit (Illumina, San Diego, CA). Single-stranded cDNA was synthesized by reverse transcription, and separately amplified with polymerase chain reaction using one of 48 primers containing index sequences (11 cycles). Using the Pippin Prep DNA Size Selection System (Sage Science, Beverley, MA), amplified cDNA constructs were purified from 3% agarose gel to isolate a library of small clone fragments. The library was sequenced on Illumina NextSeq 500, using NextSeq 75-cycle High Output Kits (Illumina), with the PhiX Control v3 library (Illumina) as sequencing control.</p><p id="Par22">Short reads were filtered for adapters and reads of low quality using Cutadapt (v.1.8) [<xref ref-type="bibr" rid="CR8">8</xref>] with error rate of 0.2 and minimum length of 18&#x000a0;bp, aligned against GENCODE human genome reference assembly GRCh38.p3 using Burrows Wheeler Aligner [<xref ref-type="bibr" rid="CR9">9</xref>], and assigned to miRBase (v.21) annotations using HTSeq (v.0.6.1p2) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Data were filtered for targets with a minimum of 10 counts in at least 50% of samples. After normalization, differentially expressed miRNAs between EBOV- and mock-infected ARPE-19 cells were identified using the DESeq 2 statistical package (v.3.2) [<xref ref-type="bibr" rid="CR12">12</xref>]. Reads were screened for complete matches to published EBOV miRNA sequences, allowing for 3 mismatches [<xref ref-type="bibr" rid="CR13">13</xref>]. Raw data from our RNA-Seq study of the total RNA transcriptome of EBOV-infected ARPE-19 cells [<xref ref-type="bibr" rid="CR5">5</xref>] (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100839">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100839</ext-link>) were processed in the same statistical pipeline used for human miRNAs, to identify genes that were differentially regulated with adjusted p-value&#x02009;&#x02264;&#x02009;0.05 and log2 fold-change&#x02009;&#x02265;&#x02009;1.</p><p id="Par23">Computational predictions of the targets of differentially expressed human miRNAs (defined by adjusted p-value&#x02009;&#x0003c;&#x02009;0.001 and log2 fold-change&#x02009;&#x0003e;&#x02009;1) were performed using public databases with different algorithms: Diana microT CDS (v.5.0) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], filtering with a threshold of 0.95; TargetScan (v.7.1) [<xref ref-type="bibr" rid="CR16">16</xref>], sorting on a total context score&#x02009;&#x0003c;&#x02009;0.15; and miRDB (v.5.0) [<xref ref-type="bibr" rid="CR17">17</xref>], with a target threshold&#x02009;&#x0003e;&#x02009;85. The human miRNAs were also input into public online repositories of experimentally-validated data on molecular interactions: miRecords (release 2013) and miRTarBase (v.7.0) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], set to &#x02018;strong evidence&#x02019;.</p><p id="Par24">Gene ontology [<xref ref-type="bibr" rid="CR20">20</xref>] and pathway analyses were performed using Cytoscape (v.3.4.0) and ClueGO (v.2.3.3) plugin [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], to identify enriched biological processes and molecular functions, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [<xref ref-type="bibr" rid="CR23">23</xref>]. Using the STRING Action dataset (v.9) within CluePedia plugin (v.1.3.3) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and collating miRNA-gene pairs, a miRNA-based network was constructed from miRNA-predicted gene target lists, miRNA-validated target gene lists, and the differentially expressed gene list; interactions were demonstrated based on degree, to identify the most highly-connected genes and miRNAs. An inverse correlation was required between expression of an miRNA and its target gene in these analyses.</p></sec><sec id="Sec4"><title>Results</title><p id="Par25">RNA sequencing yielded 1.61&#x02013;2.87&#x02009;&#x000d7;&#x02009;10<sup>7</sup> reads per replicate (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Filtering for size, 91&#x02013;97% of trimmed sequences were mapped to the human genome. 814 human miRNAs were identified (Additional file <xref rid="MOESM2" ref-type="media">2</xref>), and multidimensional scaling showed separation between results for EBOV- and mock-infected human RPE cells (Additional file <xref rid="MOESM3" ref-type="media">3</xref>). Defining differential expression as adjusted p-value&#x02009;&#x0003c;&#x02009;0.05, 28 and 61 miRNAs were significantly increased and decreased, respectively, in EBOV-infected cells. Filtering stringently for adjusted p-value&#x02009;&#x0003c;&#x02009;0.001 and log2 fold-change&#x02009;&#x0003e;&#x02009;1, 13 and 2 miRNAs were significantly increased and decreased (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). EBOV-miR-1-5p, EBOV-miR-T1-3p, EBOV-miR-T1-5p and EBOV-miR-T3-5p/T4-5p were identified in the infected human RPE cells (Additional file <xref rid="MOESM4" ref-type="media">4</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>List of miRNAs that were differentially expressed between EBOV- and mock-infected human RPE cells at 24&#x000a0;h post-infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">miRNA</th><th align="left">log2 fold-change</th><th align="left">Adjusted p-value</th></tr></thead><tbody><tr><td align="left">hsa-miR-3074-3p</td><td char="." align="char">&#x02212;&#x02009;1.52</td><td align="left">1.24&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;12</sup></td></tr><tr><td align="left">hsa-miR-27b-5p</td><td char="." align="char">&#x02212;&#x02009;1.06</td><td align="left">2.63&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup></td></tr><tr><td align="left">hsa-miR-101-5p</td><td char="." align="char">1.03</td><td align="left">3.09&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8</sup></td></tr><tr><td align="left">hsa-miR-33b-5p</td><td char="." align="char">1.04</td><td align="left">8.18&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td></tr><tr><td align="left">hsa-miR-190a-3p</td><td char="." align="char">1.06</td><td align="left">6.30&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td></tr><tr><td align="left">hsa-miR-1305</td><td char="." align="char">1.10</td><td align="left">3.92&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td></tr><tr><td align="left">hsa-miR-130a-5p</td><td char="." align="char">1.19</td><td align="left">3.15&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup></td></tr><tr><td align="left">hsa-miR-32-5p</td><td char="." align="char">1.21</td><td align="left">2.39&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td></tr><tr><td align="left">hsa-miR-365a-5p</td><td char="." align="char">1.24</td><td align="left">2.39&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup></td></tr><tr><td align="left">hsa-miR-100-3p</td><td char="." align="char">1.27</td><td align="left">1.19&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;13</sup></td></tr><tr><td align="left">hsa-miR-33b-3p</td><td char="." align="char">1.33</td><td align="left">7.05&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;10</sup></td></tr><tr><td align="left">hsa-miR-4521</td><td char="." align="char">1.37</td><td align="left">2.63E&#x02212;13</td></tr><tr><td align="left">hsa-miR-33a-5p</td><td char="." align="char">1.41</td><td align="left">5.10E&#x02212;04</td></tr><tr><td align="left">hsa-miR-29b-3p</td><td char="." align="char">1.47</td><td align="left">2.24E&#x02212;08</td></tr><tr><td align="left">hsa-miR-1307-5p</td><td char="." align="char">1.50</td><td align="left">1.98E&#x02212;10</td></tr></tbody></table></table-wrap>
</p><p id="Par26">Putative target genes in EBOV-infected human RPE cells were predicted from the 15 highly differentially expressed miRNAs using algorithms: 2629 targets by Diana microT; 1799 targets by miRDB; and 14,315 targets by TargetScan (Additional file <xref rid="MOESM5" ref-type="media">5</xref>). Targets were also identified through interrogation of experimentally validated data: 44 targets by miRecords; and 9 targets by miRTarBase (Additional file <xref rid="MOESM6" ref-type="media">6</xref>). 1440 genes were differentially expressed between EBOV- and mock-infected ARPE-19 cells (Additional file <xref rid="MOESM7" ref-type="media">7</xref>). Highly enriched gene ontology categories and KEGG pathways were established for the target genes, based on numbers represented within categories and pathways, and ranking of corrected p-values (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a&#x02013;c, Additional file <xref rid="MOESM8" ref-type="media">8</xref>). The molecular network constructed from miRNA-target gene interactions included 363 highly connected molecules; most connected molecule was leucine-rich repeat kinase 2 (LRRK2), and most connected miRNA was hsa-miR-190a (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Additional files <xref rid="MOESM9" ref-type="media">9</xref> and <xref rid="MOESM10" ref-type="media">10</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p><bold>a</bold>&#x02013;<bold>c</bold> Graphs showing enriched gene ontology categories: <bold>a</bold> biological process, <bold>b</bold> molecular function and <bold>c</bold> KEGG pathways in human RPE cells 24&#x000a0;h post-infection with EBOV. Percentages indicate proportion of known genes represented within the grouping. <bold>d</bold> Network of interactions between protein-coding genes and miRNAs in EBOV-infected human RPE cells, with miRNAs indicated by yellow diamonds, molecules indicated by blue circles, and interactions that are promoting or inhibiting represented as blue or red lines, respectively. Size of circle or diamond is proportionate to the number of molecular interactions (or degrees). An enlarged version of <bold>d</bold> is presented as Additional file <xref rid="MOESM8" ref-type="media">8</xref></p></caption><graphic xlink:href="13104_2019_4671_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>List of highly-connected protein-coding genes (16 most connected) and miRNAs (all connected in EBOV-infected human RPE cells)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein-coding genes</th><th align="left">Degree</th></tr></thead><tbody><tr><td align="left">LRRK2</td><td char="." align="char">181</td></tr><tr><td align="left">MAPK13</td><td char="." align="char">125</td></tr><tr><td align="left">MAPK7</td><td char="." align="char">117</td></tr><tr><td align="left">PRKCE</td><td char="." align="char">66</td></tr><tr><td align="left">PRKCH</td><td char="." align="char">64</td></tr><tr><td align="left">SGK494</td><td char="." align="char">64</td></tr><tr><td align="left">RND3</td><td char="." align="char">52</td></tr><tr><td align="left">DIRAS3</td><td char="." align="char">44</td></tr><tr><td align="left">RASD2</td><td char="." align="char">43</td></tr><tr><td align="left">RASL11B</td><td char="." align="char">43</td></tr><tr><td align="left">PDGFRB</td><td char="." align="char">37</td></tr><tr><td align="left">ARHGEF3</td><td char="." align="char">36</td></tr><tr><td align="left">IQGAP2</td><td char="." align="char">36</td></tr><tr><td align="left">ARL14</td><td char="." align="char">35</td></tr><tr><td align="left">ARL4A</td><td char="." align="char">35</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">miRNA</th><th align="left">Degree</th></tr></thead><tbody><tr><td align="left">hsa-miR-190a</td><td char="." align="char">58</td></tr><tr><td align="left">hsa-miR-29b-3p</td><td char="." align="char">25</td></tr><tr><td align="left">hsa-miR-130a-5p</td><td char="." align="char">17</td></tr><tr><td align="left">hsa-miR-32-5p</td><td char="." align="char">16</td></tr><tr><td align="left">hsa-miR-33a-5p</td><td char="." align="char">12</td></tr><tr><td align="left">hsa-miR-33b-5p</td><td char="." align="char">11</td></tr><tr><td align="left">hsa-miR-7-5p</td><td char="." align="char">11</td></tr><tr><td align="left">hsa-miR-33b-3p</td><td char="." align="char">7</td></tr><tr><td align="left">hsa-miR-1305</td><td char="." align="char">6</td></tr><tr><td align="left">hsa-miR-100-3p</td><td char="." align="char">5</td></tr><tr><td align="left">hsa-miR-19a-5p</td><td char="." align="char">5</td></tr><tr><td align="left">hsa-miR-101-5p</td><td char="." align="char">4</td></tr><tr><td align="left">hsa-miR-27b-5p</td><td char="." align="char">3</td></tr><tr><td align="left">hsa-miR-365a-5p</td><td char="." align="char">1</td></tr><tr><td align="left">hsa-miR-4521</td><td char="." align="char">1</td></tr></tbody></table><table-wrap-foot><p>Degree indicates number of interactions for each molecule</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec5"><title>Discussion</title><p id="Par27"><italic>Zaire ebolavirus</italic> causes uveitis in EVD survivors [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. We have identified miRNAs produced in human RPE cells following infection with EBOV. Viruses take advantage of host miRNAs to adjust gene expression and create an environment that supports replication [<xref ref-type="bibr" rid="CR28">28</xref>]. Human RPE cells make multiple molecular adjustments in response to infection with EBOV [<xref ref-type="bibr" rid="CR5">5</xref>], and miR-190a is central to the cell response. This highly connected miRNA contributes to cell survival and latency in Epstein&#x02013;Barr virus (EBV) infection, by downregulating expression of tumor protein P53 inducible nuclear protein 1 and nuclear receptor subfamily 4 group A member 3, thereby preventing cell cycle arrest and inhibiting apoptosis [<xref ref-type="bibr" rid="CR29">29</xref>]. The same mechanism may be utilized by EBOV to promote viral replication in infected RPE cells. One other interacting miRNA&#x02014;miR-101&#x02014;prevents cell death in the context of herpes simplex virus type 1 infection [<xref ref-type="bibr" rid="CR30">30</xref>], pointing to a common strategy among viruses to promote survival of both the virus and its host cell.</p><p id="Par28">Another highly connected miRNA was miR-29b3p, which suppresses key immunological pathways by downregulating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#x003ba;B) [<xref ref-type="bibr" rid="CR31">31</xref>]. This transcription factor plays an essential role in the anti-viral type IFN response. Multiple receptors&#x02014;including toll-like receptors and retinoic acid-inducible gene (RIG)-I&#x02014;stimulate NF-&#x003ba;B, which activates transcription of IFN-&#x003b2; and IFN-stimulated genes. <italic>Zaire ebolavirus</italic> profoundly inhibits the type I IFN response in monocytes and other cell populations, through the action of viral proteins&#x02014;VP24 and VP35&#x02014;and suppression of RIG-I signaling [<xref ref-type="bibr" rid="CR32">32</xref>]. Our prior work has demonstrated that EBOV-infected RPE cells mount a type I IFN response [<xref ref-type="bibr" rid="CR5">5</xref>]; however, EBOV also may suppress this pathway through activation of miR-29b-3p. Other viruses act similarly: the NF-&#x003ba;B pathway is not activated in human RPE cells infected with cytomegalovirus [<xref ref-type="bibr" rid="CR33">33</xref>]. MicroRNA-29b is also activated in Japanese encephalitis virus infection, particularly in persons with neurological sequelae, and elevated serum levels may indicate severe disease [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par29">After entering the host cell, EBOV is transported via endolysosomal trafficking [<xref ref-type="bibr" rid="CR35">35</xref>]. Infected cells also release exosomes containing EBOV VP40, which may promote leukocyte apoptosis [<xref ref-type="bibr" rid="CR36">36</xref>]. Consistent with involvement of the endolysosomal system, the most highly connected molecule in the miRNA-target gene network was LRRK2. This protein is a key regulator of the system; a range of mutations in LRRK2 result in formation of large, dysfunctional lysosomes [<xref ref-type="bibr" rid="CR37">37</xref>]. Interestingly, LRRK2 activation in microglia has been implicated in the progression of central nervous system inflammation, as occurs in Parkinson&#x02019;s disease and HIV-associated neurocognitive disorders [<xref ref-type="bibr" rid="CR38">38</xref>]. This suggests LRRK2 activity in EBOV-infected RPE cells may contribute to the development of uveitis.</p><p id="Par30">As applies to all viruses, EBOV infection involves hijacking translational machinery of the host cell to produce viral particles. Gene ontology enrichment analysis for molecular function showed strong activation of DNA-binding and transcription pathways in EBOV-infected human RPE cells. Known to bind double-stranded RNA, multiple genes in the 2&#x02032;-5&#x02032;-oligoadenylate synthetase pathway were upregulated in our gene ontology enrichment analyses, indicating a miRNA-facilitated host response to EBOV. Activation of kinases was prominent; pathways involving kinases&#x02014;such as protein kinase R&#x02014;are directly involved in the response to EBOV, binding to double-stranded RNA, activating cellular targets and inhibiting the host translational machinery [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par31">Virus-infected cells release exosomes containing host- and virus-derived miRNAs that modulate gene expression in uninfected neighbouring cells [<xref ref-type="bibr" rid="CR40">40</xref>]. Human RPE cells have the capacity to secrete exosomes containing miRNAs [<xref ref-type="bibr" rid="CR41">41</xref>]. Our data indicate that hsa-miR-27b-5p and hsa-miR-3074-3p are expressed at reduced levels when the cells become infected with EBOV, which might indicate active export of the miRNAs into exosomes. Both miRNAs are detected in the aqueous humour of healthy eyes, at levels higher than found in plasma indicating local production [<xref ref-type="bibr" rid="CR42">42</xref>]. We speculate that levels of these miRNAs might be increased in the ocular fluid of EBOV survivors, particularly those with uveitis and present biomarkers for ocular involvement. Other investigators have identified a panel of 8 serum miRNAs that predict pre-symptomatic EBOV infection, facilitating an early diagnosis of EVD [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par32">RNA viruses do not typically encode miRNAs [<xref ref-type="bibr" rid="CR28">28</xref>]. However, our analysis of EBOV-infected RPE cells identified EBOV-miR-1-5p, which has been described by several investigator teams [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. This ortholog of human miR-155 inhibits expression of importin-&#x003b1;5 and impacts type I IFN signaling [<xref ref-type="bibr" rid="CR45">45</xref>]. Molecular mimicry of miR-155 is also seen in Kaposi sarcoma herpesvirus infection of B-cells, enabling the virus to drive the cell to a state that supports long-term latency and avoids apoptosis [<xref ref-type="bibr" rid="CR46">46</xref>]. Several other EBOV-derived miRNAs were identified in the infected RPE cells, but with very low read counts suggesting negligible biological activity.</p></sec><sec id="Sec6"><title>Conclusion</title><p id="Par33">Our work provides new information about the potential post-transcriptional regulation of the human RPE cell response to infection with EBOV. Review of the biological targets of the 15 highly-induced or repressed miRNAs indicates a broad range of potential regulatory activities, including effects on immune responses, cellular metabolism, cell cycle progression, apoptosis and autophagy in the host cells. MicroRNA expression varies by tissue, including within the eye [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]; hence similar changes may not occur in other ocular tissues or tissues from other immune-privileged sites, such as testis. Future studies of the regulatory activities of these miRNAs in human RPE cells should delineate their involvement in the intraocular persistence of EBOV and EBOV-associated uveitis in EVD survivors.</p></sec></sec><sec id="Sec7"><title>Limitations</title><p>
<list list-type="bullet"><list-item><p id="Par34">We studied EBOV infection in the ARPE-19 human RPE cell line, in place of cells isolated from human eyes. This cell line is a well-characterized, robust model for studying human retinal pigment epithelium [<xref ref-type="bibr" rid="CR5">5</xref>], and thus our findings should provide reasonable fidelity to an ocular infection in an EVD survivor.</p></list-item><list-item><p id="Par35">MicroRNA expression was evaluated at one time-point post-infection. The time-point was selected in our previously published study [<xref ref-type="bibr" rid="CR7">7</xref>], to be maximally informative of host cell responses to EBOV infection, and may be most applicable to EVD and early survivorship.</p></list-item><list-item><p id="Par36">Human RPE cells were studied in isolation, while the intraocular environment includes multiple cell populations. However, this approach allowed us to focus specifically on gene expression in a key intraocular target cell for EBOV.</p></list-item><list-item><p id="Par37">Cells were infected with virulent EBOV, which caused recent EVD epidemics; less virulent <italic>Ebolavirus</italic> species may induce different miRNA expression. Cells were not co-infected with other pathogens: co-infection influences EVD outcome, which might in part reflect altered miRNA expression, as demonstrated in other infections [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].
</p></list-item></list>
</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec8"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13104_2019_4671_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold> Trimming statistics for RNA sequencing data generated for small RNA expressed in human RPE cells at 24&#x000a0;h following infection with EBOV or mock-infection.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13104_2019_4671_MOESM2_ESM.xlsx"><caption><p><bold>Additional file 2.</bold> Lists of total and differentially expressed host miRNAs expressed in human RPE cells at 24&#x000a0;h following infection with EBOV or mock-infection.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13104_2019_4671_MOESM3_ESM.tif"><caption><p><bold>Additional file 3.</bold> Graphic showing multidimensional scaling of small RNA expressed in human RPE cell at 24&#x000a0;h post-infection with EBOV.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="13104_2019_4671_MOESM4_ESM.xlsx"><caption><p><bold>Additional file 4.</bold> List of EBOV miRNAs expressed in human RPE cells at 24&#x000a0;h following infection with EBOV or mock-infection.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="13104_2019_4671_MOESM5_ESM.xlsx"><caption><p><bold>Additional file 5.</bold> List of predicted miRNA targets from Diana microT, miRDB and TargetScan databases.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="13104_2019_4671_MOESM6_ESM.xlsx"><caption><p><bold>Additional file 6.</bold> List of validated miRNA targets from miRecords and miRTarBase databases.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="13104_2019_4671_MOESM7_ESM.xlsx"><caption><p><bold>Additional file 7.</bold> List of differentially-expressed genes in human RPE cells at 24&#x000a0;h following infection with EBOV or mock-infection.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="13104_2019_4671_MOESM8_ESM.xlsx"><caption><p><bold>Additional file 8.</bold> List of enriched gene ontology categories (biological process, molecular function) and KEGG pathways for biological targets of differentially expressed miRNAs in EBOV- versus mock-infected human RPE cells.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="13104_2019_4671_MOESM9_ESM.xlsx"><caption><p><bold>Additional file 9.</bold> Results of network construction based around differentially expressed miRNAs in EBOV- versus mock-infected human RPE cells.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="13104_2019_4671_MOESM10_ESM.pdf"><caption><p><bold>Additional file 10.</bold> Enlargement of Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>cDNA</term><def><p id="Par3">complementary DNA</p></def></def-item><def-item><term>DNA</term><def><p id="Par4">deoxyribonucleic acid</p></def></def-item><def-item><term>EBOV</term><def><p id="Par5">
<italic>Zaire ebolavirus</italic>
</p></def></def-item><def-item><term>EBV</term><def><p id="Par6">Epstein&#x02013;Barr virus</p></def></def-item><def-item><term>EVD</term><def><p id="Par7">Ebola virus disease</p></def></def-item><def-item><term>IFN</term><def><p id="Par8">interferon</p></def></def-item><def-item><term>KEGG</term><def><p id="Par9">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>LRRK2</term><def><p id="Par10">leucine-rich repeat kinase 2</p></def></def-item><def-item><term>mRNA</term><def><p id="Par11">messenger RNA</p></def></def-item><def-item><term>miRNA</term><def><p id="Par12">microRNA</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p id="Par13">nuclear factor kappa-light-chain-enhancer of activated B cells</p></def></def-item><def-item><term>Nt</term><def><p id="Par14">nucleotide</p></def></def-item><def-item><term>RIG-I</term><def><p id="Par15">retinoic acid-inducible gene I</p></def></def-item><def-item><term>RNA</term><def><p id="Par16">ribonucleic acid</p></def></def-item><def-item><term>RNA-Seq</term><def><p id="Par17">RNA sequencing</p></def></def-item><def-item><term>RPE</term><def><p id="Par18">retinal pigment epithelial</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13104-019-4671-8.</p></sec><ack><title>Acknowledgements</title><p>The authors thank Dr. Renee Smith and Ms. Letitia Pimlott of the Flinders Genomics Facility, and Mr. Mark van der Hoek of the South Australian Health &#x00026; Medical Research Institute David Gunn Genomics Facility for next-generation sequencing services. The authors also thank Ms. Janet Matthews for bibliographic and other administrative support in the preparation of this manuscript.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>GFO, AO, BA, MZM, GAM and JRS conceived the study; GFO, AO, SM, MZM and GAM generated and analyzed experimental data; GO and JRS drafted the manuscript; BA, MZM and GAM provided critical review of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by: Australian Research Council (JRS: FT130101648); National Health &#x00026; Medical Research Council Australia (GFO: PGS1150282); Flinders University Faculty of Medicine, Nursing and Health Sciences (JRS); and Avant Doctor-in-Training Scholarship (GFO). The funders had no role in study design, in data collection, analysis and interpretation, or in writing the manuscript.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analysed during this study are included in this published article and its supplementary information files, with the exception of raw data files, which have been lodged in the Gene Expression Omnibus (GEO) of the National Centre for Biotechnology Information (NCBI) as GSE136985.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par38">This research involved the use of a commercially available cell line. It did not involve human participants, or the collection of human data or human tissue, and it did not involve animals. Therefore this research was not subject to ethics approval and consent to participate.</p></notes><notes><title>Consent for publication</title><p id="Par39">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par40">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattia</surname><given-names>JG</given-names></name><name><surname>Vandy</surname><given-names>MJ</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Platt</surname><given-names>DE</given-names></name><name><surname>Dierberg</surname><given-names>K</given-names></name><name><surname>Bausch</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><issue>3</issue><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00489-2</pub-id><pub-id pub-id-type="pmid">26725449</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiffany</surname><given-names>A</given-names></name><name><surname>Vetter</surname><given-names>P</given-names></name><name><surname>Mattia</surname><given-names>J</given-names></name><name><surname>Dayer</surname><given-names>JA</given-names></name><name><surname>Bartsch</surname><given-names>M</given-names></name><name><surname>Kasztura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ebola virus disease complications as experienced by survivors in Sierra Leone</article-title><source>Clin Infect Dis</source><year>2016</year><volume>62</volume><issue>11</issue><fpage>1360</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw158</pub-id><pub-id pub-id-type="pmid">27001797</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shantha</surname><given-names>JG</given-names></name><name><surname>Crozier</surname><given-names>I</given-names></name><name><surname>Hayek</surname><given-names>BR</given-names></name><name><surname>Bruce</surname><given-names>BB</given-names></name><name><surname>Gargu</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia</article-title><source>Ophthalmology</source><year>2017</year><volume>124</volume><issue>2</issue><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2016.10.011</pub-id><pub-id pub-id-type="pmid">27914832</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varkey</surname><given-names>JB</given-names></name><name><surname>Shantha</surname><given-names>JG</given-names></name><name><surname>Crozier</surname><given-names>I</given-names></name><name><surname>Kraft</surname><given-names>CS</given-names></name><name><surname>Lyon</surname><given-names>GM</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Persistence of Ebola virus in ocular fluid during convalescence [Erratum appears in N Engl J Med. 2015;372(25):2469; PMID: 26030721]</article-title><source>New Engl J Med</source><year>2015</year><volume>372</volume><issue>25</issue><fpage>2423</fpage><lpage>2427</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500306</pub-id><pub-id pub-id-type="pmid">25950269</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JR</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name><name><surname>Ashander</surname><given-names>LM</given-names></name><name><surname>Charitou</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Yeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Retinal pigment epithelial cells are a potential reservoir for Ebola virus in the human eye</article-title><source>Transl Vis Sci Technol</source><year>2017</year><volume>6</volume><issue>4</issue><fpage>12</fpage><pub-id pub-id-type="doi">10.1167/tvst.6.4.12</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drury</surname><given-names>RE</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>D</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><article-title>The clinical application of microRNAs in infectious disease</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>1182</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01182</pub-id><pub-id pub-id-type="pmid">28993774</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>KC</given-names></name><name><surname>Aotaki-Keen</surname><given-names>AE</given-names></name><name><surname>Putkey</surname><given-names>FR</given-names></name><name><surname>Hjelmeland</surname><given-names>LM</given-names></name></person-group><article-title>ARPE-19, a human retinal pigment epithelial cell line with differentiated properties</article-title><source>Exp Eye Res</source><year>1996</year><volume>62</volume><issue>2</issue><fpage>155</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1006/exer.1996.0020</pub-id><pub-id pub-id-type="pmid">8698076</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet J</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>10</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrow</surname><given-names>J</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Tapanari</surname><given-names>E</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Kokocinski</surname><given-names>F</given-names></name><etal/></person-group><article-title>GENCODE: the reference human genome annotation for The ENCODE Project</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><issue>9</issue><fpage>1760</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1101/gr.135350.111</pub-id><pub-id pub-id-type="pmid">22955987</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozomara</surname><given-names>A</given-names></name><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name></person-group><article-title>miRBase: annotating high confidence microRNAs using deep sequencing data</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><issue>D1</issue><fpage>D68</fpage><lpage>D73</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1181</pub-id><pub-id pub-id-type="pmid">24275495</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>HTSeq&#x02013;a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><issue>2</issue><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><issue>12</issue><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duy</surname><given-names>J</given-names></name><name><surname>Honko</surname><given-names>AN</given-names></name><name><surname>Altamura</surname><given-names>LA</given-names></name><name><surname>Bixler</surname><given-names>SL</given-names></name><name><surname>Wollen-Roberts</surname><given-names>S</given-names></name><name><surname>Wauquier</surname><given-names>N</given-names></name><etal/></person-group><article-title>Virus-encoded miRNAs in Ebola virus disease</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>6480</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-23916-z</pub-id><pub-id pub-id-type="pmid">29691416</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraskevopoulou</surname><given-names>MD</given-names></name><name><surname>Georgakilas</surname><given-names>G</given-names></name><name><surname>Kostoulas</surname><given-names>N</given-names></name><name><surname>Vlachos</surname><given-names>IS</given-names></name><name><surname>Vergoulis</surname><given-names>T</given-names></name><name><surname>Reczko</surname><given-names>M</given-names></name><etal/></person-group><article-title>DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><issue>W1</issue><fpage>W169</fpage><lpage>W173</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt393</pub-id><pub-id pub-id-type="pmid">23680784</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Maragkakis</surname><given-names>M</given-names></name><name><surname>Alexiou</surname><given-names>P</given-names></name><name><surname>Grosse</surname><given-names>I</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><article-title>Functional microRNA targets in protein coding sequences</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><issue>6</issue><fpage>771</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts043</pub-id><pub-id pub-id-type="pmid">22285563</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Nam</surname><given-names>JW</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Predicting effective microRNA target sites in mammalian mRNAs</article-title><source>Elife</source><year>2015</year><volume>4</volume><fpage>e05005</fpage><pub-id pub-id-type="doi">10.7554/eLife.05005</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miRDB: an online resource for microRNA target prediction and functional annotations</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>D1</issue><fpage>D146</fpage><lpage>D152</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1104</pub-id><pub-id pub-id-type="pmid">25378301</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>G</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name></person-group><article-title>miRecords: an integrated resource for microRNA-target interactions</article-title><source>Nucleic Acids Res</source><year>2009</year><volume>37</volume><issue>suppl_1</issue><fpage>D105</fpage><lpage>D110</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn851</pub-id><pub-id pub-id-type="pmid">18996891</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>NW</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>SD</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><etal/></person-group><article-title>miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><issue>D1</issue><fpage>D239</fpage><lpage>D247</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1258</pub-id><pub-id pub-id-type="pmid">26590260</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Gene ontology: tool for the unification of biology</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/75556</pub-id><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><issue>11</issue><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><name><surname>Charoentong</surname><given-names>P</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><etal/></person-group><article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><issue>8</issue><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id><pub-id pub-id-type="pmid">19237447</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name></person-group><article-title>CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><issue>5</issue><fpage>661</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt019</pub-id><pub-id pub-id-type="pmid">23325622</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Minguez</surname><given-names>P</given-names></name><etal/></person-group><article-title>The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>suppl_1</issue><fpage>D561</fpage><lpage>D568</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq973</pub-id><pub-id pub-id-type="pmid">21045058</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shantha</surname><given-names>JG</given-names></name><name><surname>Mattia</surname><given-names>JG</given-names></name><name><surname>Goba</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>KG</given-names></name><name><surname>Ebrahim</surname><given-names>FK</given-names></name><name><surname>Kraft</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Ebola virus persistence in ocular tissues and fluids (EVICT) study: reverse transcription-polymerase chain reaction and cataract surgery outcomes of Ebola survivors in Sierra Leone</article-title><source>EBioMedicine</source><year>2018</year><volume>30</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.03.020</pub-id><pub-id pub-id-type="pmid">29622497</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>JV</given-names></name></person-group><article-title>Ebola virus and persistent chronic infection: when does replication cease?</article-title><source>Ann Transl Med</source><year>2018</year><volume>6</volume><issue>Suppl 1</issue><fpage>S39</fpage><pub-id pub-id-type="doi">10.21037/atm.2018.09.60</pub-id><pub-id pub-id-type="pmid">30613614</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernier</surname><given-names>A</given-names></name><name><surname>Sagan</surname><given-names>SM</given-names></name></person-group><article-title>The diverse roles of microRNAs at the host-virus interface</article-title><source>Viruses</source><year>2018</year><volume>10</volume><issue>8</issue><fpage>440</fpage><pub-id pub-id-type="doi">10.3390/v10080440</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>EM</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>miR-190 is upregulated in Epstein&#x02013;Barr virus type I latency and modulates cellular mRNAs involved in cell survival and viral reactivation</article-title><source>Virology</source><year>2014</year><volume>464&#x02013;465</volume><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2014.06.029</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cokaric Brdovcak</surname><given-names>M</given-names></name><name><surname>Zubkovic</surname><given-names>A</given-names></name><name><surname>Jurak</surname><given-names>I</given-names></name></person-group><article-title>Herpes simplex virus 1 deregulation of host microRNAs</article-title><source>Non-coding RNA</source><year>2018</year><volume>4</volume><issue>4</issue><fpage>36</fpage><pub-id pub-id-type="doi">10.3390/ncrna4040036</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liston</surname><given-names>A</given-names></name><name><surname>Papadopoulou</surname><given-names>AS</given-names></name><name><surname>Danso-Abeam</surname><given-names>D</given-names></name><name><surname>Dooley</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-29 in the adaptive immune system: setting the threshold</article-title><source>Cell Mol Life Sci</source><year>2012</year><volume>69</volume><issue>21</issue><fpage>3533</fpage><lpage>3541</lpage><pub-id pub-id-type="doi">10.1007/s00018-012-1124-0</pub-id><pub-id pub-id-type="pmid">22971773</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>MR</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Mire</surname><given-names>CE</given-names></name><name><surname>Sureshchandra</surname><given-names>S</given-names></name><name><surname>Luthra</surname><given-names>P</given-names></name><name><surname>Yen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Differential regulation of interferon responses by Ebola and Marburg virus VP35 proteins</article-title><source>Cell Rep</source><year>2016</year><volume>14</volume><issue>7</issue><fpage>1632</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.01.049</pub-id><pub-id pub-id-type="pmid">26876165</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Margraf</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>JU</given-names></name><name><surname>Scholz</surname><given-names>M</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><issue>4</issue><fpage>1900</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.4.1900</pub-id><pub-id pub-id-type="pmid">11489969</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baluni</surname><given-names>M</given-names></name><name><surname>Ghildiyal</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Reddy</surname><given-names>DH</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Dhole</surname><given-names>TN</given-names></name></person-group><article-title>Increased serum microRNA-29b expression and bad recovery in Japanese encephalitis virus infected patients; a new component to improve the disease recovery</article-title><source>J Neuroimmunol</source><year>2018</year><volume>323</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2018.07.014</pub-id><pub-id pub-id-type="pmid">30196835</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Butz</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Wahl-Schott</surname><given-names>C</given-names></name><name><surname>Biel</surname><given-names>M</given-names></name></person-group><article-title>From mucolipidosis type IV to Ebola: TRPML and two-pore channels at the crossroads of endo-lysosomal trafficking and disease</article-title><source>Cell Calcium</source><year>2017</year><volume>67</volume><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2017.04.003</pub-id><pub-id pub-id-type="pmid">28457591</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleet</surname><given-names>ML</given-names></name><name><surname>DeMarino</surname><given-names>C</given-names></name><name><surname>Stonier</surname><given-names>SW</given-names></name><name><surname>Dye</surname><given-names>JM</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name><name><surname>Aman</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Extracellular vesicles and Ebola virus: a new mechanism of immune evasion</article-title><source>Viruses.</source><year>2019</year><volume>11</volume><issue>5</issue><fpage>410</fpage><pub-id pub-id-type="doi">10.3390/v11050410</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>AG</given-names></name><name><surname>Aghamohammadzadeh</surname><given-names>S</given-names></name><name><surname>Samaroo</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Mou</surname><given-names>K</given-names></name><name><surname>Needle</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression</article-title><source>Hum Mol Genet</source><year>2015</year><volume>24</volume><issue>21</issue><fpage>6013</fpage><lpage>6028</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv314</pub-id><pub-id pub-id-type="pmid">26251043</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puccini</surname><given-names>JM</given-names></name><name><surname>Marker</surname><given-names>DF</given-names></name><name><surname>Fitzgerald</surname><given-names>T</given-names></name><name><surname>Barbieri</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Miller-Rhodes</surname><given-names>P</given-names></name><etal/></person-group><article-title>Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><issue>13</issue><fpage>5271</fpage><lpage>5283</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0650-14.2015</pub-id><pub-id pub-id-type="pmid">25834052</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hume</surname><given-names>A</given-names></name><name><surname>Muhlberger</surname><given-names>E</given-names></name></person-group><article-title>Marburg virus viral protein 35 inhibits protein kinase R activation in a cell type-specific manner</article-title><source>J Infect Dis</source><year>2018</year><volume>218</volume><issue>suppl_5</issue><fpage>S403</fpage><lpage>S408</lpage><?supplied-pmid 30165526?><pub-id pub-id-type="pmid">30165526</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zomer</surname><given-names>A</given-names></name><name><surname>Vendrig</surname><given-names>T</given-names></name><name><surname>Hopmans</surname><given-names>ES</given-names></name><name><surname>van Eijndhoven</surname><given-names>M</given-names></name><name><surname>Middeldorp</surname><given-names>JM</given-names></name><name><surname>Pegtel</surname><given-names>DM</given-names></name></person-group><article-title>Exosomes: fit to deliver small RNA</article-title><source>Commun Integr Biol</source><year>2010</year><volume>3</volume><issue>5</issue><fpage>447</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.4161/cib.3.5.12339</pub-id><pub-id pub-id-type="pmid">21057637</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Merwe</surname><given-names>Y</given-names></name><name><surname>Steketee</surname><given-names>MB</given-names></name></person-group><article-title>Extracellular vesicles: biomarkers, therapeutics, and vehicles in the visual system</article-title><source>Curr Ophthalmol Rep</source><year>2017</year><volume>5</volume><issue>4</issue><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1007/s40135-017-0153-0</pub-id><pub-id pub-id-type="pmid">29399421</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wecker</surname><given-names>T</given-names></name><name><surname>Hoffmeier</surname><given-names>K</given-names></name><name><surname>Plotner</surname><given-names>A</given-names></name><name><surname>Gruning</surname><given-names>BA</given-names></name><name><surname>Horres</surname><given-names>R</given-names></name><name><surname>Backofen</surname><given-names>R</given-names></name><etal/></person-group><article-title>MicroRNA profiling in aqueous humor of individual human eyes by next-generation sequencing</article-title><source>Invest Ophthalmol Vis Sci</source><year>2016</year><volume>57</volume><issue>4</issue><fpage>1706</fpage><lpage>1713</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-17828</pub-id><pub-id pub-id-type="pmid">27064390</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duy</surname><given-names>J</given-names></name><name><surname>Koehler</surname><given-names>JW</given-names></name><name><surname>Honko</surname><given-names>AN</given-names></name><name><surname>Schoepp</surname><given-names>RJ</given-names></name><name><surname>Wauquier</surname><given-names>N</given-names></name><name><surname>Gonzalez</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Circulating microRNA profiles of Ebola virus infection</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>24496</fpage><pub-id pub-id-type="doi">10.1038/srep24496</pub-id><pub-id pub-id-type="pmid">27098369</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Systematic genome-wide screening and prediction of microRNAs in EBOV during the 2014 Ebolavirus outbreak</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>9912</fpage><pub-id pub-id-type="doi">10.1038/srep09912</pub-id><pub-id pub-id-type="pmid">26011078</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Ebola virus encodes a miR-155 analog to regulate importin-alpha5 expression</article-title><source>Cell Mol Life Sci</source><year>2016</year><volume>73</volume><issue>19</issue><fpage>3733</fpage><lpage>3744</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2215-0</pub-id><pub-id pub-id-type="pmid">27094387</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlke</surname><given-names>C</given-names></name><name><surname>Maul</surname><given-names>K</given-names></name><name><surname>Christalla</surname><given-names>T</given-names></name><name><surname>Walz</surname><given-names>N</given-names></name><name><surname>Schult</surname><given-names>P</given-names></name><name><surname>Stocking</surname><given-names>C</given-names></name><etal/></person-group><article-title>A microRNA encoded by Kaposi sarcoma-associated herpesvirus promotes B-cell expansion <italic>in vivo</italic></article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e49435</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0049435</pub-id><pub-id pub-id-type="pmid">23185331</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Ridzon</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Characterization of microRNA expression profiles in normal human tissues</article-title><source>BMC Genomics</source><year>2007</year><volume>8</volume><fpage>166</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-8-166</pub-id><pub-id pub-id-type="pmid">17565689</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name></person-group><article-title>MicroRNA expression in the eyes and their significance in relation to functions</article-title><source>Prog Retin Eye Res</source><year>2009</year><volume>28</volume><issue>2</issue><fpage>87</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2008.11.003</pub-id><pub-id pub-id-type="pmid">19071227</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArdle</surname><given-names>AJ</given-names></name><name><surname>Turkova</surname><given-names>A</given-names></name><name><surname>Cunnington</surname><given-names>AJ</given-names></name></person-group><article-title>When do co-infections matter?</article-title><source>Curr Opin Infect Dis</source><year>2018</year><volume>31</volume><issue>3</issue><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000447</pub-id><pub-id pub-id-type="pmid">29698255</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Swaminathan</surname><given-names>G</given-names></name><name><surname>Martin-Garcia</surname><given-names>J</given-names></name><name><surname>Navas-Martin</surname><given-names>S</given-names></name></person-group><article-title>MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy</article-title><source>Viruses</source><year>2012</year><volume>4</volume><issue>11</issue><fpage>2485</fpage><lpage>2513</lpage><pub-id pub-id-type="doi">10.3390/v4112485</pub-id><pub-id pub-id-type="pmid">23202492</pub-id></element-citation></ref></ref-list></back></article>